|Articles|October 1, 2002

New Directions for Type 2 Diabetes Mellitus Management
Volume 8
Issue 16 Suppl

Thiazolidinediones in the Treatment of Managed Care Patients with Type 2 Diabetes

Author(s)Ram Pathak, MD, Azar Afaq, MD, Lawrence Blonde, MD

Download PDF: Thiazolidinediones in the Treatment of Managed Care Patients with Type 2 Diabetes

Articles in this issue

almost 24 years ago

Article

Participating Faculty

almost 24 years ago

Article

New Directions for Type 2 Diabetes Mellitus Management

almost 24 years ago

Article

Long-term Consequences of Type 2 Diabetes Mellitus: Economic Impact on Society and Managed Care

almost 24 years ago

Article

Understanding Type 2 Diabetes Mellitus and Associated Cardiovascular Disease: Linked by Insulin Resistance

almost 24 years ago

Article

Current Treatment Approaches of Type 2 Diabetes Mellitus: Successes and Shortcomings

almost 24 years ago

Article

Effects of Thiazolidinediones for Early Treatment of Type 2 Diabetes Mellitus

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Thiazolidinediones in the Treatment of Managed Care Patients with Type 2 Diabetes

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care